- Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
On 6ix: 6ix.com/news/vera-therapeutics-announces-positive-origin-phase-3-data-atacicept-iga-nephropathy
Vera Therapeutics' next earnings callVera Therapeutics (NASDAQ:VERA) Q3 2026 Earnings Call · Nov 5, 2026 at 4:30 PM ESTRegister
Vera Therapeutics, Inc. on 6ix
In the deck
Story so far
- Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4: 30 pm ET
- Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
- Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
Earlier from Vera Therapeutics
- Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
- Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4: 30 pm ET
- Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Later from Vera Therapeutics
- Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
- Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
- Vera Therapeutics to Participate at Upcoming Investor Conferences
- Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
Follow Vera Therapeutics into a list and get an email when it puts out news.
Follow Vera Therapeutics